Legendre C, Saltiel C, Chkoff N, Kreis H
Départment de Néphrologie Hôpital Necker, Paris, France.
Clin Transpl. 1988:99-106.
From these data, it is possible to draw some partial conclusions: long-term therapy with ATG is only slightly better than a shorter course; OKT3 and ATG are both efficient in preventing rejection occurrences but OKT3 appears to be slightly better; given as prophylactic therapy, OKT3 induces better graft function; the combination of a 21-day course of OKT3 followed by CsA is probably detrimental to patients when compared to the combination of ATG + CsA.
从这些数据中，可以得出一些部分结论：抗胸腺细胞球蛋白（ATG）的长期治疗仅比短期疗程略好；OKT3和ATG在预防排斥反应发生方面均有效，但OKT3似乎略胜一筹；作为预防性治疗使用时，OKT3可诱导更好的移植肾功能；与ATG+环孢素（CsA）联合使用相比，21天疗程的OKT3随后联合CsA的方案可能对患者有害。
